-
Community Oncology Alliance Releases a Comprehensive Legislative Framework for Health Care Reform
The Community Oncology Alliance (COA) announced today the release of the COA Prescription for Health Care Reform, a comprehensive blueprint that diagnoses the fundamental challenges facing our health care system, outlines the consequences for patients across America, and presents actionable solutions that Congress must act on now to address these urgent issues.
-
COA Comments on MDPNP for IPAY 2028
The Community Oncology Alliance (“COA”) appreciates the opportunity to provide comments on the Medicare Drug Price Negotiation Program Draft Guidance (“MDPNP”) for Initial Price Applicability Year (“IPAY”) 2028 and Manufacturer Effectuation of the Maximum Fair Price (“MFP”) in 2026, 2027, and 2028.
-
COA Amicus Brief in 340B Program Rebate Model Dispute Appeal – Novartis and Bristol Myers Squibb
Pursuant to Fed. R. App. P. 29,1 amicus Community Oncology Alliance, Inc. (“COA”) submits this brief in support of Plaintiffs Appellants Novartis Pharmaceuticals Corporation (“Novartis”) and Bristol Myers Squibb Company (“BMS”). Amicus COA is a non-profit organization dedicated to representing and advocating for community oncology practices and, most importantly, the cancer patients they serve.
-
Community Oncology Alliance Applauds Senate HELP Committee Report Exposing 340B Abuses
The Community Oncology Alliance applauds U.S. Senator Bill Cassidy, M.D. (R-LA), chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee for releasing a comprehensive report detailing how large hospital systems have exploited the 340B Drug Pricing Program.
